Chemoradiotherapy-induced increase in CD4+T cell ratios can predict superior progression-free survival (PFS), while increased CD8+T cell ratios can predict improved OS in ESCC (17). This evidence concerns the gene CD4 and esophageal squamous cell carcinoma.